Both anti-HLA-A and anti-HLA-A2/Pp65 mAbs were then tested for their ability to (i) recognize target cells expressing or not HLA-A2 loaded with relevant or irrelevant peptides (ii) inhibit specific-T cell activation in a MHC or pMHC restricted manner and (iii) specifically bind HLA-A or HLA-A2/Pp65 complexes generated under naturally occurring physiological Ag-processing (i.e. viral infection) (Fig. 6). This evidence concerns the gene HLA-A and viral infectious disease.